Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Valiant Laboratories's Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹27 Mil. Therefore, Valiant Laboratories's EV-to-EBIT ratio for today is 139.70.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Valiant Laboratories's Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹87 Mil. Therefore, Valiant Laboratories's EV-to-EBITDA ratio for today is 42.98.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Valiant Laboratories (NSE:VALIANTLAB) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Valiant Laboratories's current Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Valiant Laboratories's current Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹87 Mil.
Valiant Laboratories's current Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,375 Mil.
Valiant Laboratories's current Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Valiant Laboratories's current Enterprise Value is ₹3,750 Mil.
Valiant Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories Enterprise Value Related Terms
Valiant Laboratories Enterprise Value Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Valiant Laboratories's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Enterprise Value of ₹3,750 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Valiant Laboratories and its competitors.
Is Valiant Laboratories' Enterprise Value too high?
Valiant Laboratories' current Enterprise Value is ₹3,750 Mil. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Enterprise Value compare to ZTS?
Valiant Laboratories' Enterprise Value of ₹3,750 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Valiant Laboratories and its competitors. Valiant Laboratories's current Enterprise Value is ₹3,750 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Enterprise Value is ₹3,750 Mil. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Enterprise Value is ₹3,750 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Enterprise Value: ₹3,750 Mil
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
